Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Y Wang, KCC Johnson, ME Gatti-Mays, Z Li - Journal of hematology & …, 2022 - Springer
Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-
ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable …
ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable …
TMB or not TMB as a biomarker: That is the question
Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic
options for many cancers. These treatments have demonstrated improved efficacy and often …
options for many cancers. These treatments have demonstrated improved efficacy and often …
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
Ample evidence indicates that the gut microbiome is a tumor-extrinsic factor associated with
antitumor response to anti-programmed cell death protein-1 (PD-1) therapy, but …
antitumor response to anti-programmed cell death protein-1 (PD-1) therapy, but …
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …
treatment, but current decision-making procedures have limited accuracy. In this study, we …
Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity
Defects in pathways governing genomic fidelity have been linked to improved response to
immune checkpoint blockade therapy (ICB). Pathogenic POLE/POLD1 mutations can cause …
immune checkpoint blockade therapy (ICB). Pathogenic POLE/POLD1 mutations can cause …
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments
when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) …
when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) …
Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review
S Tan, D Day, SJ Nicholls, E Segelov - Cardio Oncology, 2022 - jacc.org
Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …
Systemic immune–inflammation index predicts prognosis of cancer immunotherapy: Systemic review and meta-analysis
BW Tian, YF Yang, CC Yang, LJ Yan, ZN Ding… - …, 2022 - Future Medicine
Objective: This meta-analysis was designed to explore the association between the systemic
immune–inflammation index (SII) and the therapeutic effect of immune checkpoint inhibitors …
immune–inflammation index (SII) and the therapeutic effect of immune checkpoint inhibitors …
The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
Immune checkpoint blockade (ICB) targeting PD-1 and CTLA-4 has revolutionized cancer
treatment. However, many cancers do not respond to ICB, prompting the search for …
treatment. However, many cancers do not respond to ICB, prompting the search for …
[HTML][HTML] Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line …
JV Alessi, B Ricciuti, SL Alden, AA Bertram… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background An elevated peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is
a negative prognostic marker for patients with non-small cell lung cancer (NSCLC) receiving …
a negative prognostic marker for patients with non-small cell lung cancer (NSCLC) receiving …